Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.

about

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK.

Item

http://www.wikidata.org/entity/Q55510543

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Cost Effectiveness of Secukinu ...... ylosing Spondylitis in the UK.

@en

Cost Effectiveness of Secukinu ...... ylosing Spondylitis in the UK.

@nl

type

Item

label

Cost Effectiveness of Secukinu ...... ylosing Spondylitis in the UK.

@en

Cost Effectiveness of Secukinu ...... ylosing Spondylitis in the UK.

@nl

prefLabel

Cost Effectiveness of Secukinu ...... ylosing Spondylitis in the UK.

@en

Cost Effectiveness of Secukinu ...... ylosing Spondylitis in the UK.

@nl

P1154

2-s2.0-85047348462

http://www.w3.org/2001/XMLSchema#string

P1433

PharmacoEconomics

P1476

Cost Effectiveness of Secukinu ...... ylosing Spondylitis in the UK.

@en

P2093

Anna Halliday

http://www.w3.org/2001/XMLSchema#string

Chris Graham

http://www.w3.org/2001/XMLSchema#string

LaStella Miles

http://www.w3.org/2001/XMLSchema#string

Marjolijn Van Keep

http://www.w3.org/2001/XMLSchema#string

Praveen Gunda

http://www.w3.org/2001/XMLSchema#string

Steffen Marc Jugl

http://www.w3.org/2001/XMLSchema#string

Steve Beard

http://www.w3.org/2001/XMLSchema#string

P2860

Adverse effects of biologics: a network meta-analysis and Cochrane overview

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation

Increased mortality in ankylosing spondylitis is related to disease activity.

Diagnosis and management of ankylosing spondylitis.

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

Systematic reviews and economic evaluations conducted for the National Institute for Health and Clinical Excellence in the United Kingdom: a game of two halves?

The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis.

BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics.

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.

P2888

s40273-018-0675-9

P304

1015-1027

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-018-0675-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Paul Emery

Helena Marzo-Ortega

P5530

42545609

http://www.w3.org/2001/XMLSchema#string

P577

2018-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104169922

http://www.w3.org/2001/XMLSchema#string

P6366

2804943760

http://www.w3.org/2001/XMLSchema#string

P698

29797186

http://www.w3.org/2001/XMLSchema#string

P932

6021464

http://www.w3.org/2001/XMLSchema#string

P953

133723

s40273-018-0675-9